Early drug dosing prevents pain-related behavior in mice
Weekly dosing for five months also preserved spinal disc volume and bone structure in mice prone to early spine degeneration.
Randomized, blinded
Limit: Pain was assessed indirectly through behavioral tests
Edited by Boris Djordjevic · AgingResearch.News
In a randomized animal experiment, four-month-old male and female mice lacking the Sparc gene, a model of early spinal disc degeneration and back pain, received weekly oral doses for five months. Groups received o-vanillin at 100 milligrams per kilogram of body weight, RG-7112 at 5 milligrams per kilogram, both drugs, or a drug-free liquid. Mice without the gene deletion received the drug-free liquid for comparison.
The drugs target senescent cells, which have stopped dividing. Either drug reduced the development of sensitivity to cold compared with mice lacking Sparc given the drug-free liquid. Treated mice also had reduced expression of senescence markers and lower levels of inflammation-promoting factors in spinal tissues. Early dosing preserved bone structure. Disc volume was significantly preserved with RG-7112 and the combination, but not with o-vanillin alone.
Why it matters
Cell senescence is a hallmark of aging. The authors suggest that targeting senescent cells early could help prevent decline in muscles and bones.
Caveats
Behavioral tests are indirect measures of pain. These results came from mice genetically prone to early spine degeneration, not people.
The paper
Senolytic Therapy as a Preventive Strategy for Spine Degeneration and Pain
McGill University; Shriners Hospitals for Children - Canada
Advanced Science, May 25, 2026, Open access
